VDR and prostate carcinoma: Our large sample size, especially for patients with clinical aggressive prostate cancer, allowed us to assess the associations of 25(OH)D and 1,25(OH)2D, individually and jointly, with total and aggressive disease, as well as their potential interactions with the VDR polymorphisms.